



Eijkman Institute Jakarta Indonesia  
Persahabatan Hospital Jakarta Indonesia  
Sulianti Saroso Hospital Jakarta Indonesia  
National Institute for Health Research and Development Indonesia  
Chest Disease Institute Nonthaburi Thailand  
Bamrasnaradura Infectious Disease Hospital Nonthaburi Thailand  
Faculty of Tropical Medicine, Mahidol University Bangkok Thailand  
Queen Sirikit National Institute of Child Health Bangkok Thailand  
Siriraj Hospital Mahidol University Bangkok Thailand

National Institute for Infectious and Tropical Diseases Hanoi Vietnam  
National Hospital of Pediatrics Hanoi Vietnam  
Hospital for Tropical Diseases Ho Chi Minh City Vietnam  
Pediatric Hospital #1 Ho Chi Minh City Vietnam  
Pediatric Hospital #2 Ho Chi Minh City Vietnam  
Oxford University UK  
Wellcome Trust UK  
National Institute of Allergy and Infectious Diseases (NIAID), USA  
Center for International Research Assistance and Support (CIRAS)  
World Health Organization

## **Southeast Asia Influenza Clinical Research Network Publications Policy**

### **General Principles:**

The primary results of each study conducted by the Network are expected to be promptly shared with the scientific community through presentations at open scientific meetings and peer-reviewed publications in open-access scientific journals.

Each completed study will be written up as a Network publication that includes all the study sites and investigators that have contributed. The criteria for authorship will adhere to internationally recognized standards and be limited to those making major contributions to the study and subsequent manuscript preparation. Whenever possible, regional investigators will be given precedence in authorship decisions.

The NSC will be responsible for approving the composition of the manuscript writing group, selection of authors, public presentations and target journals, and the manuscript content prior to submission. In addition to the NSC members, other individuals with specific expertise (e.g., statistician) may be added at the discretion of the NSC or alternatively, it may seek independent review.

Following approval by the national health authorities, data from influenza sequence analyses will be put promptly into the public domain for the benefit of the scientific community at large. It will contain no clinical details and no information about the individuals concerned.

After the primary publications for a completed project are accepted for publication, each study site is free to write-up results from their own site alone as they see fit. All publications that include results funded by the Network must be agreed by the NSC, which have 30 days to consider whether the submission is appropriate. All of these publications must acknowledge the Network and funding sources.

### **Manuscript Writing Committee:**

The principal investigator for a particular study protocol will be responsible for establishing a Manuscript Writing Committee composed of key site investigators and the study statistician to develop an overall presentation strategy. Depending on the protocol and complexity of the dataset, this Group is anticipated to number 3-8 members; its composition will be approved by the NSC. The Manuscript Writing Committee will develop a plan for dissemination of the study results, including proposed meetings for presentations, numbers and content of manuscripts, and target

journals for submission. This plan will be submitted to the NSC for approval before proceeding with drafting the initial manuscript(s) that detail the primary results of this study.

Investigators within the Network who have specific ideas for a sub-study manuscript derived from the data developed in a particular study are encouraged to submit a brief summary of their concept to the Manuscript Writing Committee with copy to the NSC for consideration.

**Authorship:**

For each manuscript authors and their listing sequence will be proposed by the Manuscript Writing Committee and approved by the NSC prior to drafting the paper. The authorship for individual publications will depend on the requirements of the target journal and scope of the manuscript. In general, the number of authors from a particular site will be proportional to that sites enrollment in the study. When restrictions on author numbers are limiting, a strategy of listing one key investigator, typically the protocol principal investigator, “Nguyen Thai for the Writing Group of the Southeast Asia Influenza Clinical Research Network” or alternatively “Writing Group of the Southeast Asia Influenza Clinical Research Network” will be considered. Such manuscripts will contain an appendix that lists the members and affiliations of the Writing Group. All manuscripts will contain an appendix that lists the investigators and sites involved in the relevant protocol.

**Influenza Data Release Policy:**

1. The Network will provide open access to the comprehensive, primary sequence data after undertaking data quality control checks and obtaining approval for release from national health authorities.
2. Investigators working in the field of influenza research can request the NSC to provide access to the anonymised clinical and demographic data used by the Network in its analyses, and/or individual sequence data. Access will only be granted once the investigator has signed up to a legally-binding agreement that requires:
  - The data will only be used for influenza research;
  - The data will not be used in any way that could reasonably be expected to lead to ethnic stigmatisation;
  - No attempt will be made to identify the subjects;
  - The data will not be transferred to anyone else.
3. Data will be released via the procedures set out in points 1 and 2 above after the first publication describing the relevant Network project results has been published and obtaining approval for release from national health authorities. This publication will provide investigators with details on how to access the relevant data.
4. All data will be unlinked from personal identifiers prior to their release to maintain confidentiality.
5. This data release policy applies only to Network protocols.